Objective To analyze the efficacy of atorvastatin calcium combined with amlodipine besylate in the treatment of cerebral infarction with hypertension and its influence on the blood pressure level of patients. Methods: 100 patients with cerebral infarction and hypertension admitted to our hospital from January 2022 to December 2024 were selected as the research subjects. The patients were randomly divided into the control group and the observation group by the random number table method, with 50 cases in each group. The control group was treated with amlodipine besylate; The observation group was treated with atorvastatin calcium on the basis of the control group. The therapeutic effects, blood pressure levels [diastolic blood pressure (DBP), systolic blood pressure (SBP)], blood lipid indicators [total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C)], vascular endothelial functions [vascular endothelial growth factor (VEGF), endothelin-1 (ET-1), nitric oxide (NO)], and inflammation factors [interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP)] and adverse reactions of the two groups were analyzed and compared. Results: The total effective rate of treatment in the observation group was significantly higher than that in the control group (P < 0.05). After treatment, the levels of DBP and SBP in both groups decreased significantly compared with those before treatment, and the levels of DBP and SBP in the observation group after treatment were significantly lower than those in the control group (P < 0.05). After treatment, the levels of TC, TG and LDL-C in both groups decreased significantly compared with those before treatment, and the levels of TC, TG and LDL-C in the observation group after treatment were significantly lower than those in the control group (P < 0.05). After the treatment, the levels of VEGF and NO in both groups were significantly increased compared with those before the treatment, and the level of ET-1 was significantly decreased compared with that before the treatment. Moreover, the variation amplitudes of various vascular endothelial function indicators such as VEGF, ET-1, and NO in the observation group were significantly greater than those in the control group (P < 0.05). After treatment, the levels of IL-6 and hs-CRP in both groups decreased significantly compared with those before treatment, and the levels of IL-6 and hs-CRP in the observation group after treatment were significantly lower than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Atorvastatin calcium combined with amlodipine besylate in the treatment of patients with cerebral infarction and hypertension can improve the therapeutic effect, lower blood pressure levels, improve blood lipid levels and vascular endothelial function, reduce inflammation, and has good safety.